Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2012
11/01/2012US20120276145 Extracellular matrix proteins from haemophilus influenzae biofilms: targets for therapeutic or diagnostic use
11/01/2012US20120276144 Pro-Apoptotic Bacterial Vaccines To Enhance Cellular Immune Responses
11/01/2012US20120276143 Probiotic bifidobacterium strain
11/01/2012US20120276142 Nucleic acid sequences encoding and compositions comprising ige signal peptide and/or il-15 and methods for using the same
11/01/2012US20120276141 Env polypeptide complexes and methods of use
11/01/2012US20120276140 Compositions and methods for activating innate and allergic immunity
11/01/2012US20120276139 Use of newcastle disease virus-based vector for inducing an immune response in mammals
11/01/2012US20120276137 Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
11/01/2012US20120276136 Chemically programmable immunity
11/01/2012US20120276135 Methods for improving the design, bioavailability, and efficacy of random sequence polymer compositions via serum protein-based detection of random sequence polymer compositions
11/01/2012US20120276134 Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells
11/01/2012US20120276133 Tolerogenic synthetic nanocarriers for inducing regulatory b cells
11/01/2012US20120276132 Atoxic recombinant holotoxins of Clostridium difficile as immunogens
11/01/2012US20120276131 Anti-trypanosomiasis vaccines and diagnostics
11/01/2012US20120276130 Diagnostic and therapeutic methods for rheumatic heart disease based upon group a streptococcus markers
11/01/2012US20120276129 Neisserial antigenic peptides
11/01/2012US20120276128 HIV Envelope-CD4 Complexes and Hybrids
11/01/2012US20120276127 Treatment of retinal disorders with recombinant t cell receptor ligand (rtl)
11/01/2012US20120276126 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
11/01/2012US20120276125 Novel immunoconjugates
11/01/2012US20120276124 Maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
11/01/2012US20120276123 Anticoagulant antidotes
11/01/2012US20120276122 Methods for diagnosis and treatment of cellular proliferative disorders
11/01/2012US20120276121 Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
11/01/2012US20120276120 T-Cell Stimulating Protein B and Methods of Use
11/01/2012US20120276119 CD37-Binding Molecules and Immunoconjugates Thereof
11/01/2012US20120276118 Heterocyclic aspartyl protease inhibitors
11/01/2012US20120276117 Binding Partners for the Thyrotropin Receptor and Uses Thereof
11/01/2012US20120276116 Prevention and Treatment of Amyloidogenic Disease
11/01/2012US20120276115 Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
11/01/2012US20120276114 Ifn-gamma inhibitors in the treatment of motoneuron diseases
11/01/2012US20120276113 Methods of treating and preventing colitis involving il-13 and nk-t cells
11/01/2012US20120276112 Anti-factor xi monoclonal antibodies and methods of use thereof
11/01/2012US20120276111 Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
11/01/2012US20120276110 Modulation of Pathogenic Monocytes
11/01/2012US20120276109 Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
11/01/2012US20120276108 Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
11/01/2012US20120276107 Methods and Compositions for Mycoplasma Pneumoniae Exotoxins
11/01/2012US20120276106 Klk-13 antibody inhibitor for treating dry eye
11/01/2012US20120276105 Use of cytokine expression to predict skin inflammation; methods of treatment
11/01/2012US20120276104 Multispecific modular antibody
11/01/2012US20120276103 Vhh for application in tissue repair, organ regeneration, organ replacement and tissue engineering
11/01/2012US20120276102 Methods of treatment utiliziing binding proteins of the interleukin-21 receptor
11/01/2012US20120276101 Viral chemokine-antigen fusion proteins
11/01/2012US20120276100 Compositions and Methods of Use of Immunotoxins Comprising Ranpirnase (Rap) Show Potent Cytotoxic Activity
11/01/2012US20120276099 Monospecific polypeptide reagents
11/01/2012US20120276098 Drug fusions and conjugates with extended half life
11/01/2012US20120276097 Immunoglobulin fusion proteins
11/01/2012US20120276096 Immunoglobulin fusion proteins
11/01/2012US20120276095 B7-h4 fusion proteins and methods of use thereof
11/01/2012US20120276094 Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
11/01/2012US20120276093 Therapeutic combination comprising a cdc7 inhibitor and an anti-neoplastic agent
11/01/2012US20120276092 Antibody Glycosylation Variants
11/01/2012US20120276091 Human Recombinant Monoclonal Antibody That Specifically Binds to VCAM-1 and Inhibits Adhesion and Transmigration Between Leukocytes and Endothelial Cells
11/01/2012US20120276090 Gene recombinant antibody and antibody fragment thereof
11/01/2012US20120276089 Antibodies That Inhibit WNT Signaling And Methods Of Using The Same
11/01/2012US20120276088 Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
11/01/2012US20120276087 Methods and compositions using pde4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
11/01/2012US20120276086 Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
11/01/2012US20120276085 Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
11/01/2012US20120276084 Predicting Risk of Age-Related Macular Degeneration
11/01/2012US20120276083 Methods for inhibiting ocular angiogenesis
11/01/2012US20120276082 Treatment of cancer
11/01/2012US20120276049 Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences
11/01/2012US20120276048 Extended treatment of multiple sclerosis
11/01/2012US20120276047 Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
11/01/2012US20120276046 Anti ganglioside gd3 antibodies and uses thereof
11/01/2012US20120276045 Treatment of solid cancers
11/01/2012US20120276043 Immunoglobulin fusion proteins
11/01/2012US20120276010 Microorganisms for therapy
11/01/2012US20120276009 Pharmaceutical composition
11/01/2012US20120276000 Clec14a inhibitors
11/01/2012US20120275997 Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer
11/01/2012US20120275996 IL-1 Binding Proteins
11/01/2012CA2837367A1 Ureaplasma vaccine and antibody for prevention and treatment of human, animal and cell culture infection
11/01/2012CA2834680A1 Selecting use of proteasome inhibitors based on nf-kb2 sequence
11/01/2012CA2834599A1 Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells
11/01/2012CA2834571A1 Tolerogenic synthetic nanocarriers for inducing regulatory b cells
11/01/2012CA2834534A1 Tolerogenic synthetic nanocarriers for generating cd8+ regulatory t cells
11/01/2012CA2834533A1 Tolerogenic synthetic nanocarriers for allergy therapy
11/01/2012CA2834532A1 Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
11/01/2012CA2834527A1 Tolerogenic synthetic nanocarriers to reduce antibody responses
11/01/2012CA2834519A1 Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
11/01/2012CA2834514A1 Tolerogenic synthetic nanocarriers
11/01/2012CA2834430A1 Composition and method for predicting response to trastuzumab therapy in breast cancer patients
11/01/2012CA2834404A1 Anti-cd40 antibodies and methods of use
11/01/2012CA2834376A1 Neutralizing antibodies to nipah and hendra virus
11/01/2012CA2834349A1 Liposomal formulations
11/01/2012CA2834288A1 Truncated hiv envelope proteins (env), methods and compositions related thereto
11/01/2012CA2834243A1 Anti-human receptor-type protein tyrosine phosphatase .sigma. antibody
11/01/2012CA2834203A1 Compositions and method for treating autoimmune diseases
11/01/2012CA2834136A1 Anti-b7-h3 antibody
11/01/2012CA2833385A1 Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
11/01/2012CA2832360A1 Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
11/01/2012CA2831008A1 Novel immunoconjugates
11/01/2012CA2827952A1 Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin
10/2012
10/31/2012EP2518496A2 BMP-1 procollagen C-proteinase for diagnosis and treatment of bone and soft tissue defects and disorders
10/31/2012EP2518142A1 Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
10/31/2012EP2518085A1 IL-17 receptor A antigen binding proteins
10/31/2012EP2518083A2 Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLTL antagonist for treating cancer
1 ... 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 ... 1823